WaveMan
WaveMan · Company
PMCB · Pharmacyte Biotech, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

PMCB PharmaCyte Biotech (PMCB) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001157075
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
8
13F, latest reported quarter

PharmaCyte Biotech insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for PharmaCyte Biotech, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Silverman Joshua
CEO and President
BUY
2026-01-07 SEC
40,000
$33.2K
-62.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jan 6, 2026.
  • -7.8% median (-7.8% mean) 90-day return after 2 previous buys.
  • The trade is 9.6% of the 416,250 shares held after it.
  • 1 other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President Silverman Joshua bought about $33.2K of PMCB on Jan 7, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 8 funds added in the latest 13F quarter.
SCHECHTER JONATHAN
Director
BUY
2026-01-07 SEC
20,000
$16.8K
-62.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jan 6, 2026.
  • -7.8% median (-7.8% mean) 90-day return after 2 previous buys.
  • The trade is 10.4% of the 192,500 shares held after it.
  • 1 other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SCHECHTER JONATHAN bought about $16.8K of PMCB on Jan 7, 2026; 1 other insider bought within 30 days and 8 funds added in the latest 13F quarter.
Silverman Joshua
CEO and President
BUY
2026-01-07 SECtraded 2026-01-06
30,000
$23.7K
-62.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jan 5, 2026.
  • The trade is 8.0% of the 376,250 shares held after it.
  • 1 other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President Silverman Joshua bought about $23.7K of PMCB on Jan 6, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 8 funds added in the latest 13F quarter.
SCHECHTER JONATHAN
Director
BUY
2026-01-07 SECtraded 2026-01-06
20,000
$15.8K
-62.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jan 5, 2026.
  • The trade is 11.6% of the 172,500 shares held after it.
  • 1 other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SCHECHTER JONATHAN bought about $15.8K of PMCB on Jan 6, 2026; 1 other insider bought within 30 days and 8 funds added in the latest 13F quarter.
Silverman Joshua
CEO and President
BUY
2026-01-07 SECtraded 2026-01-05
30,000
$23.4K
-62.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 8.7% of the 346,250 shares held after it.
  • 1 other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President Silverman Joshua bought about $23.4K of PMCB on Jan 5, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 8 funds added in the latest 13F quarter.
6 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 1 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
8 funds bought in last quarter
below 89% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
$401.6K repurchased, FY to 2026-04-30
below 90% of Pharma & Biotech
Short interest
1.3% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 71% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch PMCB

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-63.5%12M
-65%-34%-3%+27%2025-102025-122026-022026-042026-062026-082026-10 2026-01-07 · Silverman Joshua bought $33.2K2026-01-06 · Silverman Joshua bought $23.7K2026-01-05 · Silverman Joshua bought $23.4K2026-01-07 · SCHECHTER JONATHAN bought $16.8K2026-01-06 · SCHECHTER JONATHAN bought $15.8K2026-01-05 · SCHECHTER JONATHAN bought $15.6K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PMCB: institutional holders (13F)

13F holdings, latest reported quarter
CITADEL ADVISORS LLC
283,381 sh
$218.2K
GEODE CAPITAL MANAGEMENT, LLC
124,247 sh
$95.7K
VANGUARD CAPITAL MANAGEMENT LLC
56,778 sh
$43.7K
SUSQUEHANNA INTERNATIONAL GROUP, LLP
44,853 sh
$34.5K
RENAISSANCE TECHNOLOGIES LLC
37,987 sh
$29.2K

Congress trades in PMCB

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PMCB planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

PMCB mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$84.7K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$21.9K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$43.7K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$10.8K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$12.7K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 8 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PMCB financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-08-01 to 2026-07-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-45.4%
TTM net income over average of 2025-07-31 and 2026-07-31
Return on assets
-39.5%
TTM net income over average of 2025-07-31 and 2026-07-31
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-17.5%
operating income (EBIT proxy) over average of 2025-07-31 and 2026-07-31 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-042025-042024-042023-04
Revenue$0$0$0$0
Operating income-$6.9M-$4.4M-$8.5M-$6.5M
Net income-$19.4M$30.7M$333.8K-$4.3M
EPS (diluted)-2.773.19-1.80-0.22
Operating cash flow-$5.2M-$3.0M-$2.2M-$3.8M
Cash$18.6M$15.2M$50.2M$68.0M
Buybacks$401.6K$2.5M$28.2M$13.6M
SEC XBRL, fiscal years, as known on 2026-10-28

PMCB Stock Sonar score 3/7 axes

Find similar shapesCompare

PMCB ranks highest on risk and compliance (67th percentile) and profitability (62nd), and lowest on institutional and government (11th), among Pharma & Biotech peers.

Profitability
62
Inputs
  • Return on equity-45.4% · 57 pct, sector of 545
  • Return on assets-39.5% · 53 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-17.5% · 75 pct, sector of 576
Institutional and government
11
Inputs
  • Funds adding, latest quarter8 · 11 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
67
Inputs
  • Short interest, % of float+1.3% · 78 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+9.4% · 56 pct, sector of 511
4 not measured: Financial health, Growth, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies